title: Prevention and treatment of osteoporosis in inflammatory bowel disease.
abstract: The following are guidelines for evaluation and consideration for treatment of patients with inflammatory bone disease (IBD) after bone mineral density (BMD) measurements. The Crohn's & Colitis Foundation of America (CCFA) has indicated that its recommendations are intended to serve as reference points for clinical decision-making, not as rigid standards, limits, or rules. They should not be interpreted as quality standards.
authors.affiliation: University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104-4283, USA. grl@uphs.upenn.edu
authors.forename: Gary R
authors.initials: GR
authors.lastname: Lichtenstein
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Sands
authors.forename: Michael
authors.initials: M
authors.lastname: Pazianas
mesh_terms: D015502:Absorptiometry, Photon; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000175:diagnosis; D016723:Bone Remodeling / Q000502:physiology; D002136:Calcium, Dietary / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D012307:Risk Factors; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D005938:Glucocorticoids; D014807:Vitamin D